Nasdaq

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)

Eliquis Offered to Cash-Paying Patients at More Than 40% Discount to Current List Price, Sotyktu at More Than 80% Discount to Current List Price PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb ...
Nasdaq

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option

Eliquis 360 Support Program Now Offers Eliquis to Cash-Paying Patients at More than 40% Discount to Current List Price PRINCETON, N.J.--(BUSINESS WIRE)-- The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY ...